SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2023 Oct 25

PMID 37877555

Authors

Richard A Teran

Alexandra Gagner

Stephanie Gretsch

Jeff Lauritsen

Daniel Galanto

Kelly Walblay

Peter Ruestow

Colin Korban

Massimo Pacilli

David Kern

Stephanie R Black

Irina Tabidze

Affiliations

Soon will be listed here.

Abstract

Understanding if persons with HIV (PWH) have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance. To determine whether HIV infection was associated with increased risk for SARS-CoV-2 reinfection, we followed adult residents of Chicago, Illinois, USA, with SARS-CoV-2 longitudinally from their first reported infection through May 31, 2022. We matched SARS-CoV-2 laboratory data and COVID-19 vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System. Among 453,587 Chicago residents with SARS-CoV-2, a total of 5% experienced a SARS-CoV-2 reinfection, including 192/2,886 (7%) PWH and 23,642/450,701 (5%) persons without HIV. We observed higher SARS-CoV-2 reinfection incidence rates among PWH (66 [95% CI 57-77] cases/1,000 person-years) than PWOH (50 [95% CI 49-51] cases/1,000 person-years). PWH had a higher adjusted rate of SARS-CoV-2 reinfection (1.46, 95% CI 1.27-1.68) than those without HIV. PWH should follow the recommended COVID-19 vaccine schedule, including booster doses.

Citing Articles

SARS-CoV-2 seroprevalence in people living with HIV in South Sudan.

Chun H, Lodiongo D, Milligan K, Lesuk G, Patel D, Shiraishi R IJID Reg. 2024; 12:100421.

PMID: 39281194 PMC: 11399597. DOI: 10.1016/j.ijregi.2024.100421.

References

Wang H, Yuan Y, Xiao M, Chen L, Zhao Y, Zhang H . Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection. Cell Mol Immunol. 2021; 18(7):1832-1834. PMC: 8182358. DOI: 10.1038/s41423-021-00708-6. View

Fontana L, Villamagna A, Sikka M, McGregor J . Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infect Control Hosp Epidemiol. 2020; 42(6):659-668. PMC: 7691645. DOI: 10.1017/ice.2020.1273. View

Tenforde M, Patel M, Gaglani M, Ginde A, Douin D, Talbot H . Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(4):118-124. PMC: 9351530. DOI: 10.15585/mmwr.mm7104a2. View

Lumley S, ODonnell D, Stoesser N, Matthews P, Howarth A, Hatch S . Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 2020; 384(6):533-540. PMC: 7781098. DOI: 10.1056/NEJMoa2034545. View

Butt A, Khan T, Yan P, Shaikh O, Omer S, Mayr F . Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination. J Infect. 2021; 83(2):237-279. PMC: 8159711. DOI: 10.1016/j.jinf.2021.05.021. View

Braunstein S, Lazar R, Wahnich A, Daskalakis D, Blackstock O . Coronavirus Disease 2019 (COVID-19) Infection Among People With Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data. Clin Infect Dis. 2020; 72(12):e1021-e1029. PMC: 7799250. DOI: 10.1093/cid/ciaa1793. View

Nevejan L, Cuypers L, Laenen L, Van Loo L, Vermeulen F, Wollants E . Early SARS-CoV-2 Reinfections within 60 Days and Implications for Retesting Policies. Emerg Infect Dis. 2022; 28(8):1729-1731. PMC: 9328893. DOI: 10.3201/eid2808.220617. View

Sheehan M, Reddy A, Rothberg M . Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis. 2021; 73(10):1882-1886. PMC: 7989568. DOI: 10.1093/cid/ciab234. View

Wheatley A, Juno J, Wang J, Selva K, Reynaldi A, Tan H . Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021; 12(1):1162. PMC: 7896046. DOI: 10.1038/s41467-021-21444-5. View

10.

Slezak J, Bruxvoort K, Fischer H, Broder B, Ackerson B, Tartof S . Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin Microbiol Infect. 2021; 27(12):1860.e7-1860.e10. PMC: 8373524. DOI: 10.1016/j.cmi.2021.07.030. View

11.

Yek C, Warner S, Wiltz J, Sun J, Adjei S, Mancera A . Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(1):19-25. PMC: 8735560. DOI: 10.15585/mmwr.mm7101a4. View

12.

Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View

13.

Plumb I, Feldstein L, Barkley E, Posner A, Bregman H, Briggs Hagen M . Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(15):549-555. PMC: 9020856. DOI: 10.15585/mmwr.mm7115e2. View

14.

Li T, Cao Z, Chen Y, Cai M, Zhang L, Xu H . Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol. 2020; 93(1):506-512. PMC: 7362127. DOI: 10.1002/jmv.26280. View

15.

Coburn S, Humes E, Lang R, Stewart C, Hogan B, Gebo K . Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. JAMA Netw Open. 2022; 5(6):e2215934. PMC: 9175076. DOI: 10.1001/jamanetworkopen.2022.15934. View

16.

. Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014; 63(RR-03):1-10. View

17.

Babiker A, Marvil C, Waggoner J, Collins M, Piantadosi A . The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. J Clin Microbiol. 2020; 59(4). PMC: 8092746. DOI: 10.1128/JCM.02769-20. View

18.

Liu C, Lee J, Ta C, Soroush A, Rogers J, Kim J . Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. JMIR Public Health Surveill. 2022; 8(5):e35311. PMC: 9132195. DOI: 10.2196/35311. View

19.

Cavanaugh A, Spicer K, Thoroughman D, Glick C, Winter K . Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(32):1081-1083. PMC: 8360277. DOI: 10.15585/mmwr.mm7032e1. View

20.

Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A . Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022; 386(13):1207-1220. PMC: 8908850. DOI: 10.1056/NEJMoa2118691. View